A Randomised Two-by-Two, Multicentre, Open-Label Phase 3 Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL....

Project Details

Short titleA Randomised Two-by-Two, Multicentre, Open-Label Phase 3 Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL....
StatusFinished
Effective start/end date1/03/0630/06/15

Funding

  • Queen Elizabeth Hospital Birmingham